Friday, July 26, 2019 (HealthDay News)-The first clinical trial in the United States to begin this fall will attempt to treat the disease using the CRISPR technology, a gene-editing technology in the body. Doctors want some kind of treatment using state-of-the-art technology. Hereditary Form of Blindness It is called Leber congenital amaurosis.
They have normal eyes, but this type of patient Blindness Lack of genes that turn light into signals to the brain to enable vision Associated Press report.
Using that tool cut Or when you “edit” DNA in a particular location, researchers seek to provide healthy versions of the missing gene to children and adult patients. The study will be attended by 18 people nationwide and will be conducted by two companies, Editas Medicine and Allergan.
Leber Congenital Amaurosis Hereditary Childhood blindness that occurs in about 2-3 out of 100,000 live births.
The only other attempt to use gene editing in the body was to treat metabolic disorders. It was done by a company called Sangamo Therapeutics. AP report.
Copyright © 2019 Health Day. all rights reserved.
The first US trial using CRISPR in the body will begin
Source link The first US trial using CRISPR in the body will begin